Last updated: February 13, 2026
What Is the Market Position of NDC: 00480-8687?
NDC 00480-8687 corresponds to Ocrevus (ocrelizumab), a monoclonal antibody used primarily for multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). Since its FDA approval in March 2017, Ocrevus has established a significant presence in the multiple sclerosis treatment landscape.
What Are the Current Market Dynamics for Ocrevus?
Market Share and Adoption
- Market share: Ocrevus holds approximately 40% of the disease-modifying therapy (DMT) market for MS in the U.S., trailing behind Tecfidera and Aubagio but gaining ground due to its efficacy profile.
- Patient population: Estimated at 1 million MS patients in the U.S., with about 15-20% exhibiting primary progressive MS.
Competitive Landscape
Prescribing Trends
- Steady growth since launch, driven by expanded indications and real-world safety data.
- Favorable positioning for patients with aggressive or progressive MS forms.
What Are Price Projections for Ocrevus?
Current Pricing
- List price: Approximately $65,000 per year per patient (per manufacturer data, 2023).
- Net revenue: Estimated at $3.3 billion in 2022 in the U.S., with global sales approaching $4.5 billion.
Market Trends Influencing Price
- Price competition: Biosimilars and new oral agents exert downward pressure.
- Formulary access: Payers increasingly favor oral agents due to cost and patient preference, potentially limiting Ocrevus's share.
- Regulatory impacts: No significant proposals to force price reductions as of 2023; reimbursement remains stable.
Future Price Projections
| Year |
Estimated Average Price (USD) |
Notes |
| 2023 |
$65,000 |
Stable, based on current list price and market uptake. |
| 2024 |
$63,000 - $65,000 |
Slight decline expected due to competitive pressures and negotiations. |
| 2025 |
$62,000 - $64,000 |
Continued downward trend, stabilization expected post-market adjustments. |
- Price reductions are likely to be limited to 2-4% annually given high efficacy and lack of biosimilar competition till 2028.
How Will Market Factors Affect Future Sales?
Impact of Biosimilars
- Biosimilar versions of ocrelizumab could enter the market post-2028, likely causing a 15-20% price reduction.
- Patent expiry extends to at least 2028, providing a window for revenue growth.
Regulatory and Policy Environment
- Payer negotiations and value-based pricing models increasingly influence manufacturer revenue.
- Potential for increased access restrictions if cost-effectiveness does not improve.
Innovation and Pipeline Developments
- Efforts to develop oral or less expensive biologics may erode market share.
- Ocrevus's position may strengthen if it maintains superior efficacy or safety profiles.
Key Takeaways
- Ocrevus (NDC 00480-8687) holds a significant segment of the MS therapeutics market, with stable growth in U.S. sales.
- The current list price hovers around $65,000 annually, with expected slight declines driven by market dynamics.
- Competition from oral agents and biosimilars will shape pricing and market share from 2028 onward.
- Patent exclusivity until at least 2028 limits biosimilar impact in the near term.
FAQs
1. What factors most influence Ocrevus's pricing?
Market competition, payor negotiations, manufacturing costs, and regulatory policies.
2. How stable are Ocrevus's sales projections?
Sales are expected to grow modestly until biosimilar entry, after which a decline of 15-20% in price and volume is anticipated.
3. When do biosimilars for ocrelizumab likely enter the market?
Post-2028, subject to patent expiry and regulatory approval.
4. How does Ocrevus compare in price to other MS therapies?
Ocrevus's list price is comparable to high-efficacy biologics like Tysabri but higher than oral agents such as Tecfidera.
5. What role will future innovations play in market dynamics?
Development of oral or less expensive biologics could reduce Ocrevus's market share and pressure pricing.
Sources
- [1] U.S. Food and Drug Administration (FDA). Ocrelizumab (Ocrevus) Approval Announcement. 2017.
- [2] IQVIA. MS Market Dynamics, 2022.
- [3] Manufacturer Price Listings, 2023.
- [4] Market Analysis Reports, 2022-2023.
- [5] Patent Expiry Data, 2023.
(Note: All figures are estimates based on publicly available data as of 2023.)
